Navigation Links
NeoStem Announces Participation in Multiple January Conferences
Date:1/4/2012

NEW YORK, Jan. 4, 2012 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that the Company and Progenitor Cell Therapy ("PCT"), will be presenting at four upcoming January conferences: Biotech Showcase 2012, BOCEMb 2012 - Noble Financial Capital Markets Equity Conference, ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies, and Phacilitate's Cell & Gene Therapy Forum 2012.

Dr. Robin L. Smith commented, "This list of January events demonstrates our widespread involvement in various industry forums and investor conferences that give us the opportunity to highlight our cell therapy industry expertise designed to put us at the forefront in transforming chronic disease through the application of cell based medicine while strategically providing revenues from our contract cGMP manufacturing of a variety of product candidates under development."

Biotech Showcase 2012 – January 10, 2012, San Francisco, California – Park 55 Wyndham8:00 – 9:30 AM – Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present as part of a panel discussion entitled "Regenerative Medicine State of the Industry Briefing."

10:30 AM – Dr. Robin L. Smith, Chairman and CEO of NeoStem, will present on NeoStem in Track C.

9:30 – 11:00 AM – Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem, will present on Amorcyte, a NeoStem company developing novel treatments for cardiovascular disease, as part of a panel discussion entitled "Cardiovascular, AMI and PAD—Part 1".

ECI's Inaugural Scale-Up and Manufacturing of Cell-Based Therapies– January 11-13, 2012, San Diego, California – Catamaran Resort Hotel10:40 AM on Thursday, January 12 – Dr. Robert A. Preti, President of PCT, will chair a session titled "Process Development Challenges f
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeoStems CEO Letter to Shareholders
2. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
3. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
4. NeoStem Announces Participation in Multiple October Conferences
5. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
6. NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
7. The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
8. NeoStem to Present at Two Investor Events This Month
9. NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development
10. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
11. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ... initiative to create the next generation of fertilizers and production technologies, with initial financial ... ... -- IFDC is launching the Virtual Fertilizer Research Center (VFRC), a global ...
... , ... ... ... , ...
... ... ... ... ...
Cached Biology Technology:IFDC Launches Virtual Fertilizer Research Center 2IFDC Launches Virtual Fertilizer Research Center 3IFDC Launches Virtual Fertilizer Research Center 4IFDC Launches Virtual Fertilizer Research Center 5Icahn Nominates 4 to Genzyme Slate 2Icahn Nominates 4 to Genzyme Slate 3Icahn Nominates 4 to Genzyme Slate 4Icahn Nominates 4 to Genzyme Slate 5Icahn Nominates 4 to Genzyme Slate 6Icahn Nominates 4 to Genzyme Slate 7Icahn Nominates 4 to Genzyme Slate 8Icahn Nominates 4 to Genzyme Slate 9Icahn Nominates 4 to Genzyme Slate 10Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 2Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 3Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 4Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 5Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 6
(Date:4/16/2014)... U.S. and beyond will convene in Lincoln, Nebraska, USA, ... existing science, and explore the unique geologic and historic ... applied geology, paleontology, and mid-continent geology. Events include a ... Kirk Johnson, Sant Director of the Smithsonian National Museum ... by the University of Nebraska-Lincoln. Lincoln is located near ...
(Date:4/16/2014)... Our ability to store memories improves during childhood, ... its connections with prefrontal and parietal cortices. New ... brain regions develop at this crucial time. Eventually, ... emerge in the transition into and during adolescence ... , Located deep in the middle of the ...
(Date:4/16/2014)... Martin Prechtl, Leo Heim and their colleagues at the ... new method of generating hydrogen using water and formaldehyde. ... interest when it comes to fuel cell technologies. The ... production using water and formaldehyde", have recently been published ... other applications, the new approach can be used to ...
Breaking Biology News(10 mins):Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4How kids' brain structures grow as memory develops 2
... the diaphragm muscles has received approval from the Food and ... Sclerosis (ALS), also known as Lou Gehrig,s disease. The ... patients breathe longer without the aid of a ventilator. ... Medical Center who helped develop and test DPS and who ...
... in the October 2011 print issue of The FASEB ... what kicks off the process that causes varicose veins. In ... binds to DNA to control gene function (called "transcription factor ... of proteins that significantly affect the development of varicose veins. ...
... work of a team of scientists at Cold Spring Harbor ... way to overcome one of the major technical obstacles preventing ... addressed successfully by novel drugs. The target is ... long known to be an important player in the signaling ...
Cached Biology News:Diaphragm pacing system receives FDA approval for use with ALS patients 2Scientists discover the proteins that control development of varicose veins 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 3Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 4